We have shown in previous studies that the DPP-4 inhibitor Linagliptin enhances the number of stroke-induced DCX+ neuroblasts in association with improved stroke recovery, even though T2D per se did not affect this cellular process [50, 65]. Here, DCX is linked to type 2 diabetes mellitus.